SCHEMBL7157753

SCHEMBL7157753

COc1cccc2c1C(S(=O)(=O)c1ccc(OCc3cccnc3)cc1)CS2(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
ADAMTS4 O75173 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
NAMPT P43490 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
FFAR1 O14842 1/20 0.37
PDE10A Q9Y233 1/20 0.37
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37
PKM P14618 1/20 0.37
ADAM17 P78536 1/20 0.37
GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7159327 0.99 HTR1A (0.40) HTR1ADRD2ADAMTS4KEAP1NFE2L2
SCHEMBL7157749 0.90 ADAMTS4 (0.41) HTR1ADRD2ADAMTS4KEAP1NFE2L2
Hydrochloric Acid SCHEMBL7159330 0.89 ADAMTS4 (0.41) HTR1ADRD2ADAMTS4KEAP1NFE2L2
SCHEMBL7132100 0.88 HTR1A (0.43) HTR1ADRD2KEAP1NFE2L2NAMPT
SCHEMBL7126862 0.83 ADAMTS4 (0.41) ADAMTS4SMN1; SMN2PKMADAM17GRM2
SCHEMBL7122877 0.81 HTR1A (0.39) HTR1ADRD2SMN1; SMN2PDE10A
SCHEMBL7129966 0.80 CYP11B1 (0.43) HTR1ADRD2NAMPTPDE4APDE4B
SCHEMBL7164804 0.80 PDE4A (0.39) HTR1APDE4APDE4BPDE4CPDE4D
SCHEMBL7132097 0.77 HTR1A (0.42) HTR1ADRD2KEAP1NFE2L2NAMPT
SCHEMBL7135542 0.77 GRM2 (0.43) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO HTR1A 4841/4885DRD2 4880/4885ADAMTS4 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.